The innovative evolution of cancer gene and cellular therapies.
We provide an overview of the latest developments in cancer gene therapy--from the bench to early-stage clinical trials. We describe the most recent work of worldwide teams including experienced scientists and clinicians, reflecting the recent emergence of gene therapy from the 'Valley of Death'. The treatment efficacy of clinical gene therapy has now been shown in a number of diseases including cancer and we are observing a renewed interest by big pharmaceutical and biotechnology companies most obviously demonstrated by Amgen's acquisition of Biovex for up to USD$1 billion. There is an opportunity to be cautiously hopeful regarding the future of gene therapy in the clinic and we review here some of the most recent progress in the field.
Division of Cellular and Molecular Research, National Cancer Centre, Singapore, Singapore.
P
P
Lam
G
G
Khan
R
R
Stripecke
K M
KM
Hui
N
N
Kasahara
K-W
KW
Peng
B-A
BA
Guinn
D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics; D064987:Cell- and Tissue-Based Therapy; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000235:genetics* / Q000628:therapy*; D057285:Precision Medicine; D034622:RNA Interference
D014408:Biomarkers, Tumor